NZ259737A - Complement-inactivating composition comprising soluble cr-1 protein and an amido-(phenyl or naphthyl) ester - Google Patents

Complement-inactivating composition comprising soluble cr-1 protein and an amido-(phenyl or naphthyl) ester

Info

Publication number
NZ259737A
NZ259737A NZ259737A NZ25973794A NZ259737A NZ 259737 A NZ259737 A NZ 259737A NZ 259737 A NZ259737 A NZ 259737A NZ 25973794 A NZ25973794 A NZ 25973794A NZ 259737 A NZ259737 A NZ 259737A
Authority
NZ
New Zealand
Prior art keywords
apan
protein
ester
soluble
complement
Prior art date
Application number
NZ259737A
Other languages
English (en)
Inventor
Danuta Ewa Irena Mossakowska
Richard Anthony Godwin Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NZ259737A publication Critical patent/NZ259737A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ259737A 1993-01-22 1994-01-21 Complement-inactivating composition comprising soluble cr-1 protein and an amido-(phenyl or naphthyl) ester NZ259737A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939301289A GB9301289D0 (en) 1993-01-22 1993-01-22 Novel composition

Publications (1)

Publication Number Publication Date
NZ259737A true NZ259737A (en) 1997-04-24

Family

ID=10729169

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ259737A NZ259737A (en) 1993-01-22 1994-01-21 Complement-inactivating composition comprising soluble cr-1 protein and an amido-(phenyl or naphthyl) ester

Country Status (10)

Country Link
EP (1) EP0680332A1 (OSRAM)
JP (1) JPH08505867A (OSRAM)
CN (1) CN1118141A (OSRAM)
AU (1) AU5863694A (OSRAM)
CA (1) CA2153797A1 (OSRAM)
GB (1) GB9301289D0 (OSRAM)
NZ (1) NZ259737A (OSRAM)
TW (1) TW241203B (OSRAM)
WO (1) WO1994016719A1 (OSRAM)
ZA (1) ZA94398B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011014A1 (en) * 1993-10-21 1995-04-27 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
GB9604518D0 (en) * 1996-03-02 1996-05-01 Smithkline Beecham Plc Novel compounds
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
JP4897690B2 (ja) * 2004-10-12 2012-03-14 ジェネンテック， インコーポレイテッド 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ191320A (en) * 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions
DE3207033C2 (de) * 1981-02-27 1984-09-13 Torii & Co., Ltd., Tokyo Amidinverbindungen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel
JPS57179147A (en) * 1981-04-28 1982-11-04 Torii Yakuhin Kk Amidine derivative
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
CA2097825A1 (en) * 1990-12-06 1992-06-07 Henry C. Marsh, Jr. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity

Also Published As

Publication number Publication date
WO1994016719A1 (en) 1994-08-04
ZA94398B (en) 1994-11-15
GB9301289D0 (en) 1993-03-17
JPH08505867A (ja) 1996-06-25
CN1118141A (zh) 1996-03-06
CA2153797A1 (en) 1994-08-04
AU5863694A (en) 1994-08-15
EP0680332A1 (en) 1995-11-08
TW241203B (OSRAM) 1995-02-21

Similar Documents

Publication Publication Date Title
EP0661992B1 (en) Pharmaceutical formulations of interleukin-1 inhibitors
US9150638B2 (en) Factor XII inhibitors for treating interstitial lung disease
TW200302105A (en) Use of PDE5 inhibitors in the treatment of scarring
SK7502002A3 (en) Pharmaceutical combinations
AU9149791A (en) Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
AU5863694A (en) Combination of a soluble complement receptor -1(scr1) and an amidinophenyl or amidino naphthyl-ester for treating inflammation
US20120020923A1 (en) Method of treating viral diseases with combinations of TPO receptor agonist and anti-viral agents
ES2268403T3 (es) Uso del metabolismo de valsartano para inhibir la agregacion de plaquetas.
US6335330B1 (en) Crystalline pharmaceutical product
US8476249B2 (en) Method of treating thrombocytopenia
Enkhbaatar et al. Recombinant tissue factor pathway inhibitor prevents lipopolysaccharide-induced systemic hypotension in rats by inhibiting excessive production of nitric oxide
JPH03133927A (ja) 虚血後の心筋機能障害の改善剤
ES2271083T3 (es) Nuevos compuestos.
CA2476446A1 (en) Use of sodium/hydrogen exchange inhibitors from the treatment of thrombotic and inflammatory diseases
US20040097583A1 (en) Use of inhibitors of the sodium/hydrogen exchanger for the treatment of thrombotic and inflammatory disorders
CN121752271A (zh) 在疾病治疗中使用的稠合哌啶基二环化合物和相关化合物
WO2004035048A1 (ja) 肝繊維化抑制剤
US20250134912A1 (en) Compositions comprising cocrystals of acetylsalicylic acid and theanine with tromethamine and methods of use
JPH07267857A (ja) 新規な炎症細胞の活性化抑制剤
JP2000007562A (ja) レトロウイルス感染に伴う免疫不全発症予防薬及び進行抑制薬
Telen GMI-1070
Mediolanum et al. INTROS
HK1097755A (en) Pharmaceutical combinations comprising a p2t receptor antagonist and another antithrombotic agent
WO2004087151A1 (ja) 医薬組成物
JPWO1989011852A1 (ja) 膵炎等治療剤